This post is also available in: עברית (Hebrew)
Lockheed Martin and Israeli StemRad are studying First-responder radiation shield for potential deep-space application. The StemRad 360 Gamma is designed to provide maxmimum protection from gamma radiation without compromising mobility.
StemRad, Ltd. and Lockheed Martin have initiated a joint research and development effort to determine if StemRad’s radiation shielding technology – originally designed for first-responders – could help to keep astronauts safe on deep-space exploration missions. This collaboration is part of Lockheed Martin’s ongoing effort to establish international partnerships for human exploration of deep space.
As designed now, the StemRad 360 Gamma is a wearable vest that protects first-responders and emergency rescue workers from dangerous gamma radiation. The design provides optimal protection of the wearer’s bone marrow stem cells, which is crucial in preventing harmful complications that can arise from radiation exposure.
Lockheed Martin is the prime contractor building Orion, NASA’s next-generation spacecraft designed to transport humans to destinations beyond low Earth orbit and bring them safely home. By providing radiation protection for long-duration missions in deep space, a successful adaptation of the commercial StemRad 360 Gamma could be a key component for ensuring astronaut health and safety.
The joint project won the support of a bilateral research committee and will be supported by grants from Space Florida, the aerospace economic development agency of Florida and MATIMOP, the executive agency of the Office of the Chief Scientist of the Ministry of Economy of Israel.
“We’re going to take our extensive knowledge of human spaceflight, apply our nano-materials engineering expertise, and working closely with StemRad, evaluate the viability for this type of radiation shielding in deep-space,” said Randy Sweet, Lockheed Martin business development director for the civil space line of business. “The Lockheed Martin team believes this could result in an innovative solution to enhance crew safety on the journey to Mars.”
Dr. Oren Milstein, co-founder and Chief Scientific Officer of StemRad commented: “We are excited to be collaborating with Lockheed Martin on this important project. Our team possesses advanced capabilities in the areas of radiation biology and innovative shielding strategies, and we will now be applying those skills to the unique challenges in human space exploration.”